<DOC>
	<DOCNO>NCT00012129</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness annamycin liposomal treat patient locally advance metastatic breast cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine observed anti-tumor activity annamycin liposomal patient anthracycline-resistant locally advanced metastatic breast cancer . II . Determine qualitative quantitative toxicity reversibility toxicity regimen patient . III . Determine clinical pharmacology regimen patient . IV . Determine rationale dose choose schedule regimen patient . OUTLINE : Patients receive annamycin liposomal IV 60 minute day 1 . Treatment continue every 3 week least 2 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 14-30 patient accrue study within 7-30 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Annamycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis locally advance metastatic breast cancer High likelihood anthracycline resistance due prior anthracycline exposure adjuvant metastatic set Prior anthraquinone ( e.g. , mitoxantrone ) insufficient Prior cumulative anthracycline dose limit doxorubicinequivalent 350 mg/m2 IV bolus 450 mg/m2 prolong ( least 48 hour ) infusion Measurable evaluable disease Brain metastasis treat prior surgery and/or radiotherapy allow neurologic status stable 2 week discontinuation dexamethasone Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No history heart failure Ejection fraction least 55 % 2dimensional echocardiogram Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Other prior malignancy allow curatively treat clear diagnosis metastatic breast cancer require treatment PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) recover Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>